Martingale Asset Management L P Has $13.34 Million Position in Qiagen (NYSE:QGEN)

Martingale Asset Management L P lowered its stake in shares of Qiagen (NYSE:QGEN) by 12.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 292,675 shares of the company’s stock after selling 40,073 shares during the period. Martingale Asset Management L P’s holdings in Qiagen were worth $13,337,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Massmutual Trust Co. FSB ADV boosted its stake in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the period. CWM LLC boosted its stake in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares during the period. Atria Investments Inc boosted its stake in shares of Qiagen by 6.0% during the 3rd quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock valued at $348,000 after buying an additional 433 shares during the period. Private Advisor Group LLC lifted its stake in shares of Qiagen by 8.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock valued at $285,000 after purchasing an additional 461 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Stock Up 1.2 %

Qiagen stock opened at $43.75 on Friday. The firm has a fifty day moving average price of $43.25 and a two-hundred day moving average price of $43.73. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The firm has a market cap of $9.98 billion, a price-to-earnings ratio of 112.18, a P/E/G ratio of 3.39 and a beta of 0.41.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.